



Original Effective Date: 02/2019
Current Effective Date: 03/10/2023
Last P&T Approval/Version: 01/25/2023
Next Review Due By: 01/2024
Policy Number: C8632-A

Linezolid

PRODUCTS AFFECTED

Zyvox (linezolid), linezolid

COVERAGE POLICY

Coverage for services, procedures, medical devices, and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide Molina Healthcare complete medical rationale when requesting any exceptions to these guidelines.

Documentation Requirements:

Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational, or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive.

DIAGNOSIS:

Nosocomial pneumonia, Community-acquired pneumonia, Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, Uncomplicated skin and skin structure infections, Vancomycin-resistant Enterococcus faecium infections, Anthrax, systemic infection; CNS infection, health care-associated (e.g., cerebrospinal fluid shunt infection); Cystic fibrosis, acute pulmonary exacerbation, moderate to severe; Endocarditis, treatment, native or prosthetic valve; Intracranial abscess (brain abscess, intracranial epidural abscess) and spinal epidural abscess; Meningitis, bacterial; Osteomyelitis and/or discitis; Prosthetic joint infection; Septic arthritis; Toxic shock syndrome; Tuberculosis, drug-resistant

REQUIRED MEDICAL INFORMATION:

This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. If a drug within this policy receives an updated FDA label within the last 180 days, medical necessity for the member will be reviewed using the updated FDA label information along with state and federal requirements, benefit being administered and formulary preferencing. Coverage will be determined on a case-by-case basis until the criteria can be updated through Molina Healthcare, Inc. clinical governance. Additional information may be required on a case-by-case basis to allow for adequate review.

Drug and Biologic Coverage Criteria

A. FOR ALL INDICATIONS:

1. Documentation member has an infection caused by or strongly suspected to be caused by a type of pathogen and site of infection within the FDA label or compendia supported
AND
2. Prescriber attests that they have reviewed the members medication profile and the member is not concurrently taking any of the following: A) monoamine oxidase (MAO) inhibitor (e.g., phenelzine, isocarboxazid), B) selective serotonin reuptake inhibitor (SSRI), C) selective norepinephrine-reuptake inhibitor (SNRI) OR the member will discontinue the concurrent interacting medication and be monitored.
AND
3. FOR IV LINEZOLID REQUESTS: Documentation that the member is converting from IV linezolid to oral linezolid OR documentation of medical necessity for continued IV therapy
AND
4. FOR PEDIATRIC REQUESTS: Documentation of member's current weight (within the last 30 days)

CONTINUATION OF THERAPY:

A. FOR INDICATIONS WITH COMPENDIA APPROVED TREATMENT > 4WEEKS:

1. Documentation member is not experiencing hematologic or neurotoxic adverse effects.
AND
2. Prescriber attests that member is being monitored for myelosuppression and changes in vision
AND
3. FOR PEDIATRIC REQUESTS: Documentation of member's current weight (within the last 30 days)

DURATION OF APPROVAL:

Initial authorization: 28 days; Continuation of Therapy: 2 months

** Linezolid is not a preferred agent for the treatment of infections requiring prolonged therapy as the risk of serious hematologic and neurologic toxicity increases after >2 weeks and >4 weeks of therapy, respectively

PRESCRIBER REQUIREMENTS:

Prescribed by or in consultation with an infectious disease specialist. [If prescribed in consultation, consultation notes must be submitted with initial request and reauthorization requests]

AGE RESTRICTIONS:

No restrictions

QUANTITY:

Dosage, frequency, and total treatment duration must be supported by FDA label or compendia supported dosing for prescribed indication

PLACE OF ADMINISTRATION:

The recommendation is that oral medications in this policy will be for pharmacy benefit coverage and patient self-administered.

The recommendation is that infused medications in this policy will be for pharmacy or medical benefit coverage administered in a place of service that is a non-inpatient hospital facility-based location.

DRUG INFORMATION

ROUTE OF ADMINISTRATION:

Oral, Intravenous

Molina Healthcare, Inc. confidential and proprietary © 2023

This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare. This page contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with Molina Healthcare.

Drug and Biologic Coverage Criteria

DRUG CLASS:

Oxazolidinones

FDA-APPROVED USES:

ZYVOX is indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria:

- Nosocomial pneumonia
- Community-acquired pneumonia
- Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis
- Uncomplicated skin and skin structure infections
- Vancomycin-resistant *Enterococcus faecium* infections.

Limitations of Use: ZYVOX is not indicated for the treatment of Gram-negative infections. The safety and efficacy of ZYVOX formulations given for longer than 28 days have not been evaluated in controlled clinical trials.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX formulations and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Zyvox is indicated for the treatment of nosocomial pneumonia caused by *Staphylococcus aureus* (methicillin-susceptible and -resistant isolates) or *Streptococcus pneumoniae*.

Zyvox is indicated for the treatment of community-acquired pneumonia caused by *Streptococcus pneumoniae*, including cases with concurrent bacteremia, or *Staphylococcus aureus* (methicillin-susceptible isolates only).

Zyvox is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by *Staphylococcus aureus* (methicillin-susceptible and -resistant isolates), *Streptococcus pyogenes*, or *Streptococcus agalactiae*. Zyvox has not been studied in the treatment of decubitus ulcers.

Zyvox is indicated for the treatment of uncomplicated skin and skin structure infections caused by *Staphylococcus aureus* (methicillin-susceptible isolates only) or *Streptococcus pyogenes*.

Zyvox is indicated for the treatment of vancomycin-resistant *Enterococcus faecium* infections, including cases with concurrent bacteremia.

COMPENDIAL APPROVED OFF-LABELED USES:

Anthrax, systemic infection; CNS infection, health care-associated (e.g., cerebrospinal fluid shunt infection); Cystic fibrosis, acute pulmonary exacerbation, moderate to severe; Endocarditis, treatment, native or prosthetic valve; Intracranial abscess (brain abscess, intracranial epidural abscess) and spinal epidural abscess; Meningitis, bacterial; Osteomyelitis and/or discitis; Prosthetic joint infection; Septic arthritis; Toxic shock syndrome; Tuberculosis, drug-resistant

APPENDIX

APPENDIX:

State Specific Information

State Medicaid

Ohio

Section: A. For All indications #2, “B) selective serotonin reuptake inhibitor (SSRI), C) selective norepinephrine-reuptake inhibitor (SNRI)” does NOT apply.

BACKGROUND AND OTHER CONSIDERATIONS

BACKGROUND:

None

Drug and Biologic Coverage Criteria

CONTRAINDICATIONS/EXCLUSIONS/DISCONTINUATION:

All other uses of linezolid are considered experimental/investigational and therefore, will follow Molina's Off-Label policy. Contraindications to linezolid include: known hypersensitivity to linezolid or any of the other product components, patients taking any monoamine oxidase inhibitors (MAOI) or within two weeks of taking an MAOI.

OTHER SPECIAL CONSIDERATIONS:

None

CODING/BILLING INFORMATION

Note: 1) This list of codes may not be all-inclusive. 2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement

HCP CODE	DESCRIPTION
J2020	injection, linezolid,200mg
J2021	Injection, linezolid (hospira) not therapeutically equivalent to J2020, 200 mg

AVAILABLE DOSAGE FORMS:

Linezolid in Sodium Chloride SOLN 600-0.9MG/300ML-%

Linezolid SOLN 600MG/300ML

Linezolid SUSR 100MG/5ML

Linezolid TABS 600MG

Zyvox SOLN 200MG/100ML

Zyvox SOLN 600MG/300ML

Zyvox SUSR 100MG/5ML

Zyvox TABS 600MG

REFERENCES

1. Zyvox (linezolid) [prescribing information]. New York, NY: Pharmacia and Upjohn; November 2021.
2. O'Driscoll T, Crank C. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. *Inf and Drug Res.* 2015; 8:217-230.
3. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. *Clin Infect Dis* 2014; Jul 15;59(2):147-59.
4. Ament PW, Jamshed, N., Horne JP. Linezolid: Its Role in the Treatment of Gram-Positive, Drug Resistant Bacterial Infections. *Am Fam Physician.* 2002 Feb 15;65(4):663-671. www.aafp.org/afp/20020215/663.html.
5. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children: executive summary. *Clin Infect Dis.* 2011;52(3):285-292. doi:10.1093/cid/cir034
6. Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. *Circulation.* 2015;132(15):1435-1486.
7. Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. *Clin Infect Dis.* 2015;61(6):e26-e46. doi:10.1093/cid/civ482

Drug and Biologic Coverage Criteria

8. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Resp Crit Care Med.* 2019;200(7):e45-e67.
doi:10.1164/rccm.201908-1581ST
9. Woods, C. R., Bradley, J. S., Chatterjee, A., Copley, L. A., Robinson, J., Kronman, M. P., . . . Lavergne,

Drug and Biologic Coverage Criteria

V. (2021). Clinical practice guideline by the Pediatric Infectious Diseases Society and the infectious diseases society of america: 2021 guideline on diagnosis and management of acute hematogenous osteomyelitis in Pediatrics. Journal of the Pediatric Infectious Diseases Society, 10(8), 801-844. doi:10.1093/jpids/piab027

SUMMARY OF REVIEW/REVISIONS	DATE
REVISION- Notable revisions: [include section header in which updates occurred] OR ANNUAL REVIEW COMPLETED- No coverage criteria changes with this annual review.	P&T QUARTER/YEAR
Q2 2022 Established tracking in new format	Historical changes on file